A Big Ten Cancer Research Consortium study, led by investigators at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, could help determine whether an investigational combination of chemotherapy drugs might lead to improved overall responses in patients with metastatic or advanced unresectable gastric/gastroesophageal junction cancer.
The goal of the single-arm, phase II study, known as BTCRC-GI15-015, is to estimate the overall objective response rate in subjects receiving the combination of FOLFOX and nab-paclitaxel (FOLFOX-A). Read More
May 1, 2018:The Big Ten Cancer Research Consortium will host meetings for the Big Ten CRC Foundation, Cancer Center Directors, Steering Committee, and Clinical Trial Working Groups during ASCO 2018. Read More
April 16, 2018: Every month, we huddle for another edition of Across the Consortium to recap the progress of our member institutions. Here are this month's hand-picked highlights from across the consortium! Be inspired as you catch all the action. Read More
April 14, 2018: As stated in the American Cancer Society’s Cancer Facts & Figures, in 2018, there will be an estimated 1,735,350 new cancer cases diagnosed and 609,640 cancer deaths in the United States. While cancer treatments and early detection have become more and more promising over the years – thus increasing life expectancy and lowering the mortality rate of cancer patients – prevention remains one of the most important challenges. Read More
March 25, 2018:Across the Consortium is your instant replay of Big Ten CRC member news. This month we highlight colon cancer screen options and advice; advancements in technology to provide better understanding of cancer spread; new strategy for treating pancreatic cancer; cutting edge cell therapies; and more! Read More
March 5, 2018: What do plant molecular biologists, chemical engineers, veterinarians, biomedical engineers, and analytical chemists from around the world have in common? Everything - at Purdue University - including correlative cancer research. "We work with people across campus and across the state that need our particular technical expertise," says Jill Hutchcroft, PhD, director of Purdue's Flow Cytometry and Cell Separation Facility. Purdue researchers in Dr. Jill Hutchcroft's lab"Our samples come from engineers, biologists, and chemists; our technology bridges many disciplines as people are trying to cross boundaries," says Hutchcroft. "We are really a connection between many different disciplines. We work with everything from human tumors to zebra fish to corn, and we work with many model systems. Our work... Read More
March 1, 2018:Investigator Spotlight Nancy Chan, MD, medical oncologist, Rutgers Cancer Institute of New JerseyResearch interests: I am interested in discovering and developing new therapies for the treatment of breast and gynecological malignancies. I have witnessed various immunotherapies shrink tumors within weeks and help women live longer with their cancer with minimal side effects. I have also faced the frustration of lack of response and rare but life... Read More
Feb. 28, 2018: Transforming the conduct of cancer research is not just a goal of Big Ten CRC members; it is reality. From zebrafish to cell phones, and from nanomedicine to "supportive oncology," the Big Ten CRC's unique team-research culture is driving science rapidly from ideas to new approaches to cancer treatment. See for yourself in a quick trip Across the Consortium! Read More
Feb. 1, 2018:Investigator Spotlight: Attaya Suvannasankha, MD, Indiana University Melvin and Bren Simon Cancer Center School of Medicine: Chulalongkorn University, Bangkok, Thailand; Residency: Einstein Medical Center Philadelphia; Fellowship: Roswell Park Cancer Institute, Buffalo, NY Research interests: Multiple myeloma is a rare and incurable blood cancer, but not all myeloma is the same. While the current treatments may work well initially, myeloma keeps recurring and eventually patients die from drug resistant myeloma and treatment side effects. Much work is needed to understand why myeloma cancer cells respond differently to common treatments. Currently, there is not a good way to predetermine the... Read More
Jan. 29, 2018: Breast cancer researchers have made great strides in recent years, identifying distinct molecular subtypes of the disease and potential novel treatment approaches. One such approach involves a type of immunotherapy, called an immune checkpoint inhibitor, that can help the immune system recognize and kill cancer cells. Pictured from left: Kim Hirshfield, MD, PhD; Deborah Toppmeyer, MD; Nancy Chan, MDImmune checkpoint inhibitors have shown promising results in a variety of research studies, and have been approved by the U.S. Food and Drug Administration to treat a variety of other cancers. In breast cancer research, much attention has been focused on triple-negative disease, or cancers in which the three most common receptors that fuel breast cancer growth - estrogen receptor, progesterone receptor, and... Read More
Subscribe to the Big Ten CRC Newsletter
X
Facebook
YouTube